


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): Pyrazolopyrimidinethione derivatives having the structure of formula I:




Wherein: R₁, R₂, and R₃ are same or different, and independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₄ is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₅ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₆ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkyl having 1-6 carbon atoms.

2. (currently amended): The pyrazolopyrimidinethione derivatives according to claim 1, characterized in that: said derivatives have the structure of formula II,



II

Wherein, R₁, R₂, R₃, R₄, and R₅ ~~dependently~~independently are alkyl having 1-6 carbon atoms.

3. (original): The pyrazolopyrimidinethione derivatives according to claim 1, wherein said pyrazolopyrimidinethione derivatives are:

5-[2-methoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H -pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-ethoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H -pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-propoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-methoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H -pyrazolo[4,3-d]pyrimidin-7-thione;

5-[2-ethoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H -pyrazolo[4,3-d]pyrimidin-7-thione; or

5-[2-propoxy-5-(cis-3,5-dimethylpiperazin-1-sulfonyl)phenyl]-1-ethyl-3-n-propyl-1,6-dihydro-7H -pyrazolo[4,3-d]pyrimidin-7-thione.



4. (original): The salts of pyrazolopyrimidinethione derivatives according to any one of claims 1-3, characterized in that: said salts are salts of organic acids or inorganic acids.

5. (original): The salts according to claim 4, characterized in that: said salts of organic acids are citrate, fumarate, oxalate, malate, lactate, camphorsulfonate, p-toluenesulfonate, or

methanesulfonate; said salts of inorganic acids are salts of haloid acid, sulfate, phosphate, or nitrate.

6. (original): The solvates of the compounds according to any one of claims 1-5, characterized in that: the solvents are water, ethanol, or methanol.

7. (original): A method for preparing the pyrazolopyrimidinethione derivatives of claim 1, comprising reacting the compound of formula III with the compound of formula IV to give said pyrazolopyrimidinethione derivatives;



Wherein: in the compounds of formulas III and IV, R₁, R₂, and R₃ are same or different, and independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₄ is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;


R₅ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, aryl having 6-10 carbon atoms, or alkyloyl having 1-6 carbon atoms;

R₆ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkyloyl having 1-6 carbon atoms; and


Y is Cl, F, Br, or I.

8. (original): The method according to claim 7, characterized in that: the solvents used in the reaction are chloroform, tetrahydrofuran, dioxane, ethanol, 1,2-dimethoxyethane, xylene, toluene, dimethyl sulfoxide, or triethylamine.


9. (original): A method for preparing the pyrazolopyrimidinethione derivatives of claim 1, comprising firstly reacting the compound of formula V with the compound of formula IV to give the compound of formula VI, and then sulfurizing said compound of formula VI to give said pyrazolopyrimidinethione derivatives;



(V)



(IV)



(VI)

Wherein: in the compounds of formula IV, V, and VI, R₁, R₂, and R₃ are same or different, and independently are alkyl having 1-6 carbon atoms, alkyl having 1-6 carbon atoms in which at least one hydrogen atom is substituted by alkoxy having 1-6 carbon atoms or cycloalkyloxy having 3-6 carbon atoms, alkenyl having 2-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₄ is alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, alkoxy having 1-6 carbon atoms, cycloalkyloxy having 3-6 carbon atoms, or aryl having 6-10 carbon atoms;

R₅ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, aryl having 6-10 carbon atoms, or alkyloyl having 1-6 carbon atoms;

R₆ is hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 3-6 carbon atoms, cycloalkyl having 3-8 carbon atoms, or alkyloyl having 1-6 carbon atoms; and

Y is Cl, F, Br, or I.

10. (original): The method according to claim 9, characterized in that: the solvent for sulfurization reaction is tetrahydrofuran, dioxane, 1,2-dimethoxyethane, ethanol, xylene, toluene, dimethyl sulfoxide, or triethylamine.

11. (original): The method according to claim 10, characterized in that: the sulfurating reagent for said sulfurization is phosphorus pentasulfide or 2,4-Bis(p-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide, and derivatives thereof, and the temperature is -20-200°C.

12. (original): A method for preparing the salts of pyrazolopyrimidinethione derivatives of claim 4, comprising reacting said pyrazolopyrimidinethione derivatives of claim 1 with the pharmaceutically acceptable acids to give said salts.

13. (original): A pharmaceutical comprising the pyrazolopyrimidinethione derivatives of claim 1, or 2, or 3 as the active ingredient, for preventing and/or treating impotence.

14. (original): A pharmaceutical comprising the pyrazolopyrimidinethione derivatives of claim 1, or 2, or 3 as the active ingredient, for preventing and/or treating frigidity.

15. (original): A pharmaceutical comprising salts of the pyrazolopyrimidinethione derivatives of claim 4 or 5 as the active ingredient, for preventing and/or treating impotence.

16. (original): A pharmaceutical comprising salts of the pyrazolopyrimidinethione derivatives of claim 4 or 5 as the active ingredient, for preventing and/or treating frigidity.

17. (original): A pharmaceutical comprising solvates of the pyrazolopyrimidinethione derivatives of claim 6 as the active ingredient, for preventing and/or treating impotence.

18. (original): A pharmaceutical comprising solvates of the pyrazolopyrimidinethione derivatives of claim 6 as the active ingredient, for preventing and/or treating frigidity.

19. (original): A pharmaceutical comprising the pyrazolopyrimidinethione derivatives of claim 1, or 2, or 3, or salts or solvates thereof, as the active ingredient for preventing and/or treating impotence and frigidity.

20. (original): The pharmaceutical according to claim 19, characterized in that: said pharmaceutical further comprises a pharmaceutically acceptable diluent or carrier.